Year: 2021
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2021
May 19, 2021
Bergen, Norway, 19 May 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…
Read MoreBERGENBIO ANNOUNCES TOP LINE DATA FROM PHASE II TRIAL ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
May 18, 2021
The trial BGBC020 shows that Bemcentinib has the potential to increase the rate of ventilator free survival…
Read MoreBERGENBIO TO PRESENT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
April 28, 2021
Bergen, Norway, 28 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO PRE-CLINICAL COVID-19 DATA TO BE PRESENTED AT VIRTUAL IMMUNOLOGY 2021
April 26, 2021
Bergen, Norway, 26 April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO ANNOUNCES UPDATE FROM INVESTIGATIONAL PHASE II TRIALS ASSESSING BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
April 19, 2021
· Day 29 follow-up of last patient enrolled has now occurred in BGBC020 and ACCORD2_002·…
Read MoreBERGENBIO ANNOUNCES STOPPED RECRUITMENT TO THE BEMCENTINIB ARM IN UK ACCORD COVID PLATFORM TRIAL
March 30, 2021
Bergen, Norway, 30 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read More
